

Evidence for Abasic Site Sugar Phosphate-Mediated Cytotoxicity in Alkylating Agent Treated *Saccharomyces cerevisiae*

Michelle Heacock[‡], Vladimir Poltoratsky^{‡*}, Rajendra Prasad, Samuel H. Wilson*

Laboratory of Structural Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, United States of America

Abstract

To better understand alkylating agent-induced cytotoxicity and the base lesion DNA repair process in *Saccharomyces cerevisiae*, we replaced the *RAD27*^{FEN1} open reading frame (ORF) with the ORF of the bifunctional human repair enzyme DNA polymerase (Pol) β . The aim was to probe the effect of removal of the incised abasic site 5'-sugar phosphate group (i.e., 5'-deoxyribose phosphate or 5'-dRP) in protection against methyl methanesulfonate (MMS)-induced cytotoxicity. In *S. cerevisiae*, Rad27^{FEN1} was suggested to protect against MMS-induced cytotoxicity by excising multinucleotide flaps generated during repair. However, we proposed that the repair intermediate with a blocked 5'-end, i.e., 5'-dRP group, is the actual cytotoxic lesion. In providing a 5'-dRP group removal function mediated by dRP lyase activity of Pol β , the effects of the 5'-dRP group were separated from those of the multinucleotide flap itself. Human Pol β was expressed in *S. cerevisiae*, and this partially rescued the MMS hypersensitivity observed with *rad27*^{FEN1}-null cells. To explore this rescue effect, altered forms of Pol β with site-directed eliminations of either the 5'-dRP lyase or polymerase activity were expressed in *rad27*^{FEN1}-null cells. The 5'-dRP lyase, but not the polymerase activity, conferred the resistance to MMS. These results suggest that after MMS exposure, the 5'-dRP group in the repair intermediate is cytotoxic and that Rad27^{FEN1} protection against MMS in wild-type cells is due to elimination of the 5'-dRP group.

Citation: Heacock M, Poltoratsky V, Prasad R, Wilson SH (2012) Evidence for Abasic Site Sugar Phosphate-Mediated Cytotoxicity in Alkylating Agent Treated *Saccharomyces cerevisiae*. PLoS ONE 7(10): e47945. doi:10.1371/journal.pone.0047945

Editor: Beata G. Vertessy, Institute of Enzymology of the Hungarian Academy of Science, Hungary

Received: July 23, 2012; **Accepted:** September 25, 2012; **Published:** October 29, 2012

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This work was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences [project number Z01ES050159]. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: wilson5@niehs.nih.gov

‡ These authors contributed equally to this work.

‡ Current address: Department of Pharmaceutical Sciences, St. John's University, Queens, New York, United States of America

Introduction

Endogenous and exogenous agents constantly damage the genome in all organisms. This damage must be repaired for the cell to avoid genomic instability or cell death. To counteract DNA damage, organisms employ several distinct DNA repair pathways that are designed to correct specific types of DNA damage. Base excision repair (BER) is one such pathway repairing smaller base lesions, single-strand breaks in DNA, and abasic sites resulting from spontaneous hydrolysis at the glycosidic bond. In the case of base lesions, repair is usually initiated by a lesion-specific DNA glycosylase. Glycosylases are classified as either monofunctional or bifunctional. Monofunctional glycosylases remove a damaged base leaving the abasic site in double-stranded DNA, while bifunctional glycosylases perform base removal and have the additional function of lyase-mediated incision of the phosphodiester DNA backbone leaving a single-strand break [1].

The BER sub-pathway that is utilized for repair of methylated DNA bases, arising after cell treatment with the DNA methylating agent methyl methanesulfonate (MMS), involves base removal by the monofunctional DNA glycosylase termed MAG [1,2]. This is

followed by DNA strand incision by an AP endonuclease, creating a 1-nt gap with 5'-deoxyribose phosphate (5'-dRP) and 3'-OH groups at the margins [1,3]. This 5'-dRP group provides an important role in mammalian BER where it is recognized by the BER factor PARP-1 [4] that promotes recruitment of other repair factors to the BER intermediate [5]. In mammalian BER, the 5'-dRP group is removed by Pol β and this enzyme also inserts a single nucleotide to fill the gap [6]. Thus, Pol β has two functions in mammalian BER, and the respective enzymatic activities are carried in dedicated domains: the 8-kDa dRP lyase domain and 31-kDa DNA polymerase domain [7]. It was shown previously that these respective activities could be eliminated by site-directed alterations of amino acids without substantially altering the other activity. Thus, strategic Lys to Ala substitutions in the dRP lyase active site (i.e., Lys35, Lys68 and Lys72 to Ala) eliminate the dRP lyase activity with little effect on the polymerase activity, and similarly, an Asp to Ala substitution in the polymerase active site (i.e., D256A) eliminates the polymerase activity without changing the dRP lyase activity [8].

In many organisms studied to date, the BER process occurs by two sub-pathways differentiated by repair patch size and the

Table 1. *S. cerevisiae* strains used in this study.

Wild type strain background is: MATα-HML/Rδ <i>leu2-3112 ade5-1 his 7-2 ura3δ trp1-289 BAR+</i> [(chr II) <i>lys2::Alu-DIR-LEU2-lys2δ5'</i>] [16]			
Name	Strain	Relevant Genotype	Source
<i>rad27Δ</i>	VP101	<i>rad27::CORE</i>	This study
<i>rad27::POLβ</i>	VP102	<i>rad27::POLβ-WT</i>	This study
<i>rad27::polβ-D256A</i>	MH101	<i>rad27::polβ-D256A</i>	This study
<i>rad27::polβ-3K</i>	MH102	<i>rad27::polβ-3K</i>	This study
Wild type strain background for <i>mre11</i> and <i>rad50</i> is MATα <i>his3Δ10 leu2Δ10 met15Δ10 ura3Δ10</i> (Research Genetics, Inc., Huntsville, AL)			
Name	Strain	Relevant Genotype	Source
<i>mre11Δ</i>	<i>mre11::KanMX</i>	<i>mre11::KanMX</i>	Research Genetics, Inc., Huntsville, AL
<i>rad50Δ</i>	<i>rad50::KanMX</i>	<i>rad50::KanMX</i>	Research Genetics, Inc., Huntsville, AL

doi:10.1371/journal.pone.0047945.t001

factors involved. These sub-pathways are termed single-nucleotide (SN) or short patch BER (insertion of only one nucleotide into the repair patch) and long patch (LP) BER (insertion of 2 or more nucleotides into the repair patch) [9,10]. Higher eukaryotes often appear to preferentially use SN BER to remove the 5'-dRP group and fill the 1-nt gap, except in cases where a modified 5'-dRP group is refractory to the dRP lyase activity. In a case, where the dRP lyase activity of Pol β is unable to remove a dRP group, LP BER is evoked [6]. LP BER is achieved either through strand-displacement DNA synthesis by replicative and repair DNA polymerases along with Fen1 flap excision or by coordinated action of Pol β and Fen1 [11], in both cases creating a substrate for DNA ligation. While higher eukaryotes are able to perform both sub-pathways of BER, *S. cerevisiae* appears to rely primarily on LP BER and on other repair pathways to repair smaller base lesions [12].

A model for repair of methylated bases in *S. cerevisiae* begins with the same upstream BER events as summarized above for mammalian cells. The DNA glycosylase responsible for removal of methylated bases, methylpurine DNA glycosylase, creates an abasic site intermediate [2]. Strand incision by AP endonuclease (APN1) creates the 5'-dRP group at the margin of a single-nucleotide gap. Next, the gap and strand break are processed by LP BER or mobilized to participate in recombinational repair.

The deletion of *RAD27^{FEN1}* in *S. cerevisiae* is known to render these cells hypersensitive to MMS [13,14,15]. However, it has not been clear whether this is due to: 1) the alkylated base lesions themselves, 2) the persistence of repair intermediates such as the abasic site or the 5'-dRP group in the repair intermediate, 3) the accumulation of a toxic multinucleotide flap [16,17]. One approach toward clarifying the picture is to express an enzyme dedicated to removing the 5'-dRP group in the repair intermediate in a *rad27^{fen1}*-null background. Thus, Pol β expression would be expected to provide for 5'-dRP group removal. In the work described here we found that deletion of *RAD27^{FEN1}* resulted in hypersensitivity to MMS, as expected [13,14,15], and human Pol β expression partially rescued the MMS hypersensitivity imposed by *RAD27^{FEN1}* deletion. It was the 5'-dRP lyase function of Pol β , not the DNA polymerase function, that conferred resistance to MMS. The results are discussed in the context of toxicity of the 5'-dRP blocking group during repair in *S. cerevisiae*.

Materials and Methods

Materials

Synthetic oligodeoxyribonucleotides were from Oligos Etc., Inc. (Wilsonville, OR) and The Midland Certified Reagent Co. (Midland, TX). [α -³²P]dCTP and [α -³²P] 3'-deoxyadenosine (Cordycepin) (3000 Ci/mmol) were from GE Healthcare (Piscataway, NJ). [γ -³²P]ATP (7000 Ci/mmol) was from Biomedicals (Irvine, CA). Optikinase and terminal deoxynucleotidyl transferase were from USB Corp. (Cleveland, OH) and Fermentas Inc. (Hanover, MD). Recombinant human Pol β was overexpressed and purified as described previously [18]. Human uracil DNA glycosylase with 84 amino acids deleted from the amino-terminus and DNA ligase I were purified as described previously [19,20]. Protease inhibitor tablets were from Roche (Indianapolis, IN). MMS and camptothecin (CPT) were from Sigma-Aldrich (St. Louis, MO). Phusion polymerase was from New England Biolabs (Ipswich, MA). Goat-anti-mouse secondary antibody conjugated to horseradish peroxidase (HRP) was purchased from Bio-Rad (Hercules, CA). Super Signal West Pico Western Blot Substrate (ECL) and Restore Western Blot Stripping Buffer were from Pierce Biotechnology Inc. (Rockford, IL). Mouse anti-GAPDH antibody was obtained from Alpha Diagnostics (San Antonio, TX).

Strain construction

All strains (Table 1) were derived from the yeast strains ALE1000 and ALE1001 (*MAT α -HML/R δ leu2-3112 ade5-1 his 7-2 ura3 δ trp1-289 BAR+* [(chr II) *lys2::Alu-DIR-LEU2-lys2 δ 5'*]). The *rad27::CORE* strain (*rad27 Δ*) was constructed by inserting the delitto perfetto *CORE-I-SCEI* cassette containing URA3 and hygromycin (HYGRO) markers [21] into the *RAD27* locus. The *CORE-I-SCEI* was amplified using the forward primer, Rad27-coref, 5' ATATACATCGATGAAAAGCGTTGACAGCATA-CATTGGAAAGAAATAGGAAACGGAACCGGAAGAAAAA-ATTAGGGATAACAGGGTAATCCGCGCGTTGGCCGATTCAT 3' and the reverse primer, Rad27corer, 5' GTATA-CAAATATCTATGTTACATATATGCCAAGGTGAAAGGAC-CAAAAGAAGAAAGTGAAAAAGAACCCCTCATTCGT-ACGCTGCAGGTCGAC 3'. Hygromycin-resistant transformants were selected following the methods described by Storici and Resnick [21]. These transformants were genotyped using the Rad27f, 5' CGTAACATCGCGCAAATGAAGGTT 3' and the Rad27r, 5' TATTAGAAATTCCACCGGCACCTG 3' primers. The *rad27::POL β* strain was constructed using homologous recombination of a PCR product generated using the Polbrad27f,




Figure 1. Strategy for introduction of a human DNA *POLβ* open reading frame into the *S. cerevisiae* genome. (A) Schematic representation of the *RAD27* gene (~1600 bp) of *S. cerevisiae* is shown. The positions of the *RAD27* 5' and 3' homologous recombination integration sites (5' and 3' HR sites, respectively), relative to the 5' and 3' regions of the *Rad27* gene, are indicated. The positions of the forward primer (Rad27f) and the reverse primer (Rad27r) used for genotyping are also illustrated. (B) First, the *CORE-I-SCEI* was amplified using the Rad27coref and Rad27corer primers. The *rad27::CORE* strain was constructed by homologous recombination of a PCR product containing the *CORE-I-SCEI* cassette containing *URA3* and hygromycin (*HYGRO*) markers flanked by up-and-downstream *RAD27* sequence. Hygromycin-resistant transformants were genotyped using the Rad27f and Rad27r primers. Correct integration of the *CORE* cassette resulted in a PCR product of ~3900 bp. Failure to integrate resulted in wild-type product of ~1600 bp. (C) The strains of *rad27::POLβ*, *rad27::polβ-D256A*, and *rad27::polβ-3K* were generated by homologous recombination of a PCR product of *POLB* open reading frame using primers Polβrad27f and Polβrad27r. Replacement of the *CORE* cassette by human *POLβ* open reading frame was confirmed using primers Rad27f and Rad27r that resulted in a PCR product of ~1500 bp.
doi:10.1371/journal.pone.0047945.g001

5' TATATACATCGATGAAAAGCGTTGACAGCATAACAT-TGGAAAGAAATAGGAAACGGACACCGGAAGAAAAAAT-ATGTCTAAACGGAAGCGCCGCAG 3' and the Polβrad27r, 5'GTATACAAATATCTATGTTACATATATGCCAAGGTG-AAGGACCAAAAAGAAGAAATGGGAAAAAGAACCCTC-ATTCGCTCCGGTCCTGGGGTTC 3' primers. The PCR product was amplified using either wild-type Pol β, polymerase-deficient Pol β (*polβ-D256A*) or lyase-deficient Pol β (*polβ K35A/K68A/K72A*) and termed as *polβ-3K* cDNA as a substrate [8]. PCR reactions (50 μl total volume) consisted of 10 ng of DNA substrate, 0.2 μM of each primer, 50 μM of dNTPs, 1× reaction buffer (50 mM KCl, 20 mM Tris-HCl, pH 8.4, 1.5 mM MgCl₂, 0.05% Tween-20), 1 U of Phusion polymerase. The two cycle PCR program 98°C 2 min, 5 cycles of 98°C 10 sec, 55°C 30 sec, 72°C 1 min was followed by 20 cycles of 98°C 10 sec, 68°C 30 sec, 72°C 1 min with a final extension of 7 min. PCR products were purified using Qiagen columns, eluted in 50 μl water and 1 μg was used in each transformation using the LiCl method. Transformation of PCR products were made into the *rad27::CORE* strain. Positive transformants were obtained by their ability to grow on 5-fluoroorotic acid followed by PCR genotyping using primers upstream and downstream of the *RAD27* locus with the forward primer, Rad27f, 5' CGTAACATCGCGCAAATGAAGTT 3' and the reverse primer, Rad27r, 5' TATTAGAAATTCAC-CCGGCACCTG 3'. All strains were sequenced to verify the respective *POLβ* mutation.

Immunoblotting

Total protein extracts were prepared using 25 ml of mid-log phase cells. Cells were collected by centrifugation and resuspended in 500 μl ice-cold lysis buffer (25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 100 mM NaCl, and 10 mM β-mercaptoethanol, supplemented with a protease inhibitor tablet). Cells were disrupted using the glass bead method, adding an equal volume of 500 μl glass beads and vortexing using 1-min increments, placing samples on ice between vortexing cycles. Protein concentration was determined using the Bradford method. Protein extract (50 μg) mixed with SDS-PAGE loading buffer was used per lane. Proteins were separated in a 4–12% Bis-Tris polyacrylamide gel electrophoresis. Proteins were transferred onto a nitrocellulose membrane using wet transfer. After blocking with 5% milk in Tris-buffered saline containing Tween 20, the membrane was incubated for at least 2 h with a mouse monoclonal antibody to Pol β (18S). Goat anti-mouse conjugated to HRP was used as a secondary antibody (1:5000 dilution), and the HRP activity was detected by enhanced chemiluminescence using SuperSignal West Pico Chemiluminescent substrate. For loading controls, blots were stripped using Restore Western Blot Stripping Buffer, probed with mouse anti-GAPDH (1:10000 dilution) and visualized as above.

Preparation of 5'- and 3'-end labeled substrates for dRP lyase assays

Preparation of the 5'- or 3'-end ³²P-labeled DNA substrate for dRP lyase assay was as follows. Dephosphorylated 19-mer




Figure 2. Expression of human *POLβ* into *S. cerevisiae rad27* mutants. (A) Immunoblot illustrating human Pol β expression in *S. cerevisiae*. Total extract protein was isolated (see Materials and Methods) from the indicated five strains. The indicated extracts (50 μl each) from *wild-type* (lane 1), *rad27Δ* (lane 2), *rad27::POLβ* (lane 3), *rad27::polβ-D256A* (lane 4), or *rad27::polβ-3K* (lane 5), respectively, were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and probed either with an antibody against pol β (upper panel) or with an antibody against GAPDH (bottom panel). Bands corresponding to Pol β (39 kDa) were observed. GAPDH was used as a loading control. (B and C) 5'-dRP lyase assays. Schematic representations of the dRP lyase substrates (3'- or 5'-end ³²P-labeled) and the expected ³²P-labeled products formed as a result of lyase activity of the extract are illustrated. (B) DNA substrate (100 nM) was incubated with extracts from *wild-type* (lane 1), *rad27Δ* (lane 2), *rad27::POLβ* (lane 3), *rad27::polβ-D256A* (lane 4), and *rad27::polβ-3K* (lane 5), with purified Pol β (lane 6), or with DNA alone (lane 7). After a 15-min incubation at 35°C, the DNA products were stabilized by NaBH₄ and analyzed as described under Material and Methods. The positions of the substrate and product are indicated. (C) 5'-end ³²P-labeled DNA substrate (100 nM) was incubated either with DNA alone (lanes 1–2) or with extracts from *wild-type* (lanes 3–4), *rad27Δ* (lanes 5–6), *rad27::POLβ* (lanes 7–8), *rad27::polβ-D256A* (lanes 9–10), and *rad27::polβ-3K* (lane 11–12), respectively. After 5 and 10 min incubations at 35°C, the DNA products were stabilized and processed as in (B). The position of the product is indicated.
doi:10.1371/journal.pone.0047945.g002

oligodeoxyribonucleotide (5'-UGTACGGATCCCCGGGTAC-3') containing a uracil residue at the 5'-end or 3'-end was phosphorylated with Optikinase and [γ -³²P]ATP or 3'-end with terminal deoxynucleotidyl transferase and [α -³²P] Cordycepin,

respectively. A 34-mer (5'-GTACCCGGGGATCCG-TACGGCGCATCAGCTGCAG-3') template was then annealed with 15-mer (5'-CTGCAGCTGATGCGC-3') and 19-mer ³²P-labeled oligonucleotides by heating the solution at 90°C for 3 min




Figure 3. *In vitro* BER capacity of *S. cerevisiae* extracts. (A) Schematic representations of the substrate and the reaction scheme are shown. (B) Repair reactions (15 μ l each) were incubated either with extracts from *wild-type* (lanes 1–3), *rad27* Δ (lanes 4–6), *rad27::POL* β (lanes 7–9), *rad27::pol* β -D256A (lanes 10–12), or *rad27::pol* β -3K (lanes 13–15), respectively. Note that all the reaction mixtures were supplemented with human DNA ligase I (200 nM). Aliquots (4.5 μ l each) were withdrawn at 2, 5 and 10 min. The repair reaction was terminated by addition of an equal volume of DNA gel-loading buffer. After incubation at 75°C for 2 min, the reaction products were separated by electrophoresis in a 16% polyacrylamide gel containing 8 M urea. A Typhoon PhosphorImager was used for gel scanning and imaging. The positions of ligated BER product and un-ligated BER intermediate are indicated.

doi:10.1371/journal.pone.0047945.g003

and allowing the solution to slowly cool to 25°C. Unincorporated [γ -³²P]ATP or [α -³²P] Cordycepin was removed by using a MicroSpinTM G-25 column (GE HealthCare) using the manufacturer's suggested protocol.

dRP lyase assay

dRP lyase activity was measured essentially as described previously [22]. Briefly, the reaction mixture (10 μ l) contained 50 mM HEPES, pH 7.5, 20 mM KCl, 2 mM dithiothreitol, 0.5 mM EDTA, 5 mM MgCl₂, and 100 nM 3'-end ³²P-labeled uracil-containing DNA substrate. The reaction was initiated by adding 4 μ g yeast extract or Pol β (10 nM). In the case of purified Pol β , the reaction mixture contained DNA substrate pre-treated with UDG. The incubation was for 15 min at 35°C. After the incubation, the reaction products were stabilized by the addition of freshly prepared 20 mM NaBH₄, then transferred to 0–1°C (on ice) and incubation continued for 30 min on ice. After further incubation at 75°C for 2 min, the reaction products were separated by electrophoresis in a 16% polyacrylamide gel containing 8 M urea in 89 mM Tris-HCl, 89 mM boric acid, and 2 mM EDTA, pH 8.8. Imaging and data analysis were performed by PhosphorImagerTM and ImageQuantTM software. In an alternate dRP lyase reaction, the dRP lyase reaction was performed as above, except 5'-end labeled DNA substrate was used.

In vitro BER assay

To perform the uracil-initiated SN BER with yeast extracts, a 35-base pair oligonucleotide duplex DNA containing uracil at

position 15 was used. The BER reaction mixture (15 μ l final volume) that contained 50 mM HEPES, pH 7.5, 0.5 mM EDTA, 2 mM dithiothreitol, 20 mM KCl, 4 mM ATP, 5 mM phosphocreatine, 100 μ g/ml phosphocreatine kinase, 0.5 mM NAD⁺, 5 mM MgCl₂, 200 nM DNA ligase I, 200 nM uracil-containing DNA, and 2.3 μ M [α -³²P]dCTP (specific activity, 1 \times 10⁶ dpm/pmol) was assembled on ice. The repair reaction was initiated by the addition of 6 μ g yeast extract and incubation at 35°C. Aliquots (4.5 μ l) were withdrawn at the indicated time intervals. Reactions were terminated by the addition of an equal volume (4.5 μ l) of DNA gel-loading buffer. After incubation at 75°C for 2 min, the reaction products were processed as above.

Primer extension assay

The primer extension assay system involved a 36-mer template strand annealed with a 17-mer 5'-³²P-labeled primer; the template strand ahead of the primer was single-stranded. The reaction mixture (15 μ l final volume) containing 50 mM HEPES, pH 7.5, 0.5 mM EDTA, 2 mM dithiothreitol, 20 mM KCl, 10 mM MgCl₂, 100 μ M dNTPs, and 200 nM DNA was assembled on ice. The repair reaction was initiated by the addition of 9 μ g yeast extract and incubation at 35°C. Aliquots (4.5 μ l) were withdrawn at 15, 30 and 60 min. Reactions were terminated by the addition of an equal volume (4.5 μ l) of DNA gel-loading buffer. After incubation at 75°C for 2 min, the reaction products were processed as above.




Figure 4. *In vitro* BER capacity of *S. cerevisiae* extracts. (A) Repair reactions were incubated either with extracts from *wild-type* (lanes 1–4), *rad27* Δ (lanes 5–8), *rad27::POL* β (lanes 9–10), *rad27::pol* β -D256A (lanes 11–14), or *rad27::pol* β -3K (lanes 15–16), respectively. Note that all the reaction mixtures were supplemented with human DNA ligase I (200 nM) as in Figure 4. Reaction mixtures were incubated at 35°C and samples were withdrawn at the indicated periods. After incubation, the reaction products were processed as in Figure 3. The positions of ligated BER product and un-ligated BER intermediate are indicated. (B) Lanes 1 to 8 from the panel (A) were exposed for a longer time to observe BER products in the *wild-type* (lanes 1–4) and *rad27* Δ (lanes 5–8) strains.
doi:10.1371/journal.pone.0047945.g004

MMS sensitivity spot dilution assay

Each strain was freshly streaked onto yeast peptone dextrose adenine (YPDA) plates from frozen stocks and used to start 5 ml liquid YPDA cultures that were grown overnight. A fresh culture of the same volume was prepared by inoculation with the overnight culture and allowed to grow at least 4 h (until reaching an OD₆₀₀ of ~0.5, where the OD₆₀₀ was normalized for each strain using the lowest OD₆₀₀). Ten-fold dilutions (shown on plates) were set-up for each strain and cultures (5 μ l of each dilution) were spotted onto YPDA plates containing either no MMS (mock), 0.5, or 1.0 mM MMS. Plates were incubated at 30°C and photographed 2–3 days after growth. All experiments were done in triplicate.

CPT sensitivity spot dilution assay

A 10 mM stock solution of CPT was prepared by dissolving it in dimethyl sulfoxide (DMSO) and aliquots were stored at -20°C

until use. Dilutions of each strain and culture were performed as described above, except cultures were spotted onto plates containing DMSO alone (mock), 25 μ M or 50 μ M CPT. Results with 25 μ M CPT are shown. All experiments were done in triplicate.

Gamma irradiation spot dilution assay

Each strain was diluted and spotted as described for MMS sensitivity spot assays. Immediately upon drying, plates containing the spotted dilutions were subjected to mock, 200 or 600 Gray of γ -irradiation using a ¹³⁷Cs irradiator. Results with 200 Gray of γ -irradiation are shown. Photographs were taken 3 days after plating.




Figure 5. *In vitro* primer extension assay by *S. cerevisiae* extracts. (A) Schematic representations of the substrate and the reaction scheme are shown. (B) The primer extension reaction mixture was incubated either with reaction mixture alone (lane 1), or with extracts from *wild-type* (lanes 2–4), *rad27Δ* (lanes 5–7), *rad27::POLβ* (lanes 8–10), *rad27::polβ-D256A* (lanes 11–13), *rad27::polβ-3K* (lanes 14–16), and purified pol β (lanes 17–19), respectively. Reaction mixtures were incubated at 35°C and samples were withdrawn at the indicated periods. After incubation, the reaction products were processed as in Figure 3. The positions of ³²P-primer and the extension products are indicated. doi:10.1371/journal.pone.0047945.g005

Results

Human Pol β is expressed in active form in *S. cerevisiae*

We developed a system for study of 5'-dRP group toxicity in *S. cerevisiae* by deleting the *RAD27* gene and inserting the *POLβ* ORF in its place, under control of the *RAD27* promoter (Figure 1). Thus, we prepared a strain with full-length wild-type human *POLβ* at the *RAD27* locus and two strains with point mutations eliminating the respective activities in each of the *POLβ* domains, a polymerase-deficient mutant (*polβ-D256A*) [23] and a lyase-deficient mutant (*polβ-3K*) [8]. The strains are summarized in Table I, and features of the strains are summarized in Figure 1.

First, to verify Pol β expression in the strains, we performed immunoblotting analysis of whole cell extracts using an anti-Pol β antibody (Figure 2A). Pol β was present in all three strains where the *POLβ* ORF had been introduced and the levels appeared to be similar (Figure 2A, lanes 3–5); in the cases of the wild-type and *rad27*-deletion strains (*rad27Δ*, Figure 2A, lanes 1 and 2), no signal was observed corresponding to Pol β, as expected.

We also used these cell extracts to verify the functional status of the dRP lyase activity of the different forms of expressed Pol β. Two assays designed to measure removal of the 5'-dRP group from oligonucleotide substrates were used (Figure 2B and C). The dRP lyase activity was functional in the *rad27::POLβ* and *rad27::polβ-D256A* strains (Figure 2B, lanes 3 and 4), but not in the wild-type, *rad27Δ*, or *rad27::polβ-3K* strain (Figure 2B, lanes 1,

2 and 5), as expected. These results were confirmed by making use an alternate assay for dRP lyase activity (see Figure 2C). In this alternate assay, the substrate contained a ³²P-labeled dRP flap in a single-nucleotide gap, as shown at the top of Figure 2C. The results obtained with this assay were similar to those obtained with the other assay (Figure 2B). Note that the wild-type and *rad27Δ* strains exhibited relatively weak dRP lyase activity (Figure 2B and C).

BER status of the strains

To evaluate the status of BER in strains studied here, we characterized the *in vitro* BER capacity of cell extracts (Figure S1). A BER substrate was incubated with extracts as described in Material and Methods. Initial experiments were conducted with the wild-type and *rad27::POLβ* strain extracts. Extract from the wild-type strain had minimal BER activity (Figure S1, lanes 1–3); in the *rad27::POLβ* extract, strong BER gap-filling synthesis was observed, as indicated by the incorporation of radiolabeled dCMP (Figure S1, lanes 4–6). Yet, the complete repair product was not observed. Addition of purified DNA ligase I, however, resulted in strong synthesis of the ligated BER product (Figure S1, lanes 7–9). These results indicated only weak BER activity in the wild-type extract, as previously observed [24], and also suggested a deficiency in DNA ligase activity in the extracts. Therefore, in further assays purified DNA ligase I was included in the reaction mixtures.




Figure 6. Human *POLβ* rescues MMS sensitivity in *S. cerevisiae*, null for *rad27*. Experiments were conducted as described in Materials and Methods. Briefly, ten-fold dilutions (as shown) were set-up for each strain and culture (5 μ l of each dilution) were spotted onto freshly prepared YPDA plates containing the indicated concentration of MMS. Photographs were taken on day 3 or 4 after plating. (A) Mock treatment, lanes 1–4; 0.5 mM MMS treatment, lanes 5–8; 1 mM MMS treatment, lanes 9–12. (B) Rescue of MMS sensitivity by human Pol β dRP lyase. Sensitivity to MMS was scored by spotting cultures of various strains on plates either without (mock) or with 1 mM of MMS. Resistance to MMS was observed in *rad27* null strains that contain *POLβ* or *polβ-D256A*. Lack of cell growth was observed only in the *rad27* null strains (*rad27Δ*) or the strain containing mutations in the dRP lyase domain (*rad27::polβ-3K*). Strains are indicated on the left. doi:10.1371/journal.pone.0047945.g006

To evaluate the *in vitro* BER activity of the strains with mutant forms of Pol β , BER assays were conducted using extracts from the complete panel of strains (Figures 3 and 4). Under the reaction condition, wild-type, *rad27Δ* and *rad27::polβ-256A* extracts showed negligible BER activity (Figure 3, lanes 1–6 and 10–12). In contrast, the *rad27::POLβ* extract was active for BER. With the *rad27::polβ-3K* extract, formation of some ligated product was detected, but the amount was less than in the *rad27::POLβ* extract. These results indicated that endogenous 5'-dRP lyase activity was present, but was insufficient to complement the Pol β 5'-dRP lyase deficiency of the *rad27::polβ-3K* strain (Figure 3, lanes 13–15); nevertheless, the production of some full-length BER product in these reactions indicated that the 5'-dRP group had been removed from at least a portion of the gap-filled BER intermediates.

The fact that negligible BER activity was observed with the wild-type and *rad27Δ* extracts raised a concern that the extracts were somehow denatured or defective for DNA synthesis. Therefore, to evaluate this, the BER reaction mixtures were incubated for extended periods as compared to the BER reactions in Figure 3. Under these reaction conditions, formation of some un-ligated BER intermediates was observed, yet the BER capacity of these extracts was minimal (Figure 4 A and B). Next, we conducted DNA polymerase primer extension experiments with the extracts. These experiments revealed that the extracts were capable of DNA polymerase activity in a primer extension assay with an open template strand ahead of the primer (Figure 5). Thus, the extracts were functional for DNA synthesis activity, and the fact that negligible or weak BER activity was observed with wild-type and other extracts (Figure 3, lanes 1–6 and 10–12) appeared to be due to the substrate specificity of the endogenous DNA polymerases.

Human *POLβ* partially rescues MMS sensitivity observed in the absence of *RAD27*

Deletion of *RAD27* causes a hypersensitivity phenotype following exposure of the DNA methylating agent MMS [13,14,15]. To test the ability of Pol β to rescue this MMS hypersensitivity, we used spot dilution assays on YPDA plates containing two concentrations of MMS (0.5 and 1 mM). Both *rad27Δ* and *rad27::POLβ* strains were able to grow on control (mock) plates that did not contain MMS (Figure 6A). On plates containing MMS, cell growth was diminished with the strain deleted for *RAD27*, indicating hypersensitivity. The MMS sensitivity was less when the *POLβ* ORF was expressed in the *rad27*-deleted strain (Figure 6A).

The 5'-dRP lyase of Pol β is required for rescue of MMS sensitivity

Pol β is a bifunctional BER enzyme and catalyzes two distinct reactions, namely dRP lyase and DNA polymerase. We utilized the strains described above to determine the contribution of each enzymatic function in protection against MMS (Figure 6B). All strains grew well on control (mock) plates. Sensitivity to 1 mM MMS was pronounced in the lyase-deficient strains, *rad27Δ* and *rad27::polβ-3K*. However, sensitivity was less with the *POLβ* wild-type (*rad27::POLβ*) strain and the polymerase deficient-lyase proficient (*rad27::polβ-D256A*) strain (Figure 6B). The results demonstrated that the Pol β -dependent protection against MMS cytotoxicity in the absence of Rad27 did not require the polymerase activity, but instead the dRP lyase function was critical. These results also indicated that the Pol β DNA polymerase activity itself did not promote cytotoxicity.




Figure 7. Rescue of CPT and ionizing radiation sensitivity by human Pol β dRP lyase. (A) Ten-fold dilutions of each indicated strain were spotted onto plates containing either DMSO alone (mock, lanes 1–5) or 25 μM CPT (lanes 6–10). *POLβ* strains were not sensitive to CPT, an agent that produced 3' blocking groups. *mre11Δ* and *rad50Δ* deleted strains were used as positive controls for CPT-sensitivity. (B) *POLβ* strains do not display sensitivity to ionizing radiation (IR), an agent that produces predominantly 3' blocking groups. As in (A), *mre11Δ* and *rad50Δ* deleted strains were used as positive controls for IR sensitivity. Indicated strains were plated and treated as described in Material and Methods, and were mock-treated (lanes 1–5) or subjected to 200 Gray (Gy) of IR, lanes 6–10. doi:10.1371/journal.pone.0047945.g007

The failure of the lyase-deficient strain to rescue MMS sensitivity may be caused by accumulation of unligatable nicks with the 5'-dRP blocking group. A prediction of this interpretation is that strains deficient in 5'-dRP lyase function would not be selectively affected by damaging agents that fail to result the 5'-dRP blocking group. Therefore, we next examined the sensitivity of the strains to CPT. Since CPT acts by trapping the topoisomerase enzyme at the 3'-margin of a single-strand break, a 5'-dRP blocking group is not involved in the repair. Multiple strains were grown on plates containing 25 μM CPT (Figure 7A). Sensitivity was not observed for any of the strains plated on mock plates (DMSO only), and sensitivity was apparent for the positive control *mre11Δ* and *rad50Δ* strains that are known to be CPT-sensitive [25]. Interestingly, differential sensitivity was not observed for wild-type and *rad27Δ* strains or for the *rad27::polβ-D256A* and *rad27::polβ-3K* strains. Finally, similar results were obtained when the strains were exposed to ionizing radiation (Figure 7B), a DNA damaging agent, like CPT, that is not expected to result in repair intermediates with the 5'-dRP group. Together, these observations are consistent with the idea that

MMS sensitivity observed in the *rad27Δ* and *rad27::polβ-3K* strains was due to the persistence of the 5'-dRP group.

Discussion

S. cerevisiae cells lacking Rad27 exhibited hypersensitivity to MMS, and we were able to examine the reason for this cytotoxicity by expression of human Pol β. By removing the *RAD27* ORF and replacing it with the *POLβ* ORF, we found that wild-type Pol β expression was sufficient to partially rescue the MMS hypersensitivity conferred by the *RAD27* deficiency. This rescue was provided by the 5'-dRP lyase function of Pol β rather than the DNA polymerase gap-filling function. Thus, the separation of function for the two Pol β enzyme activities provided a useful tool toward attributing the cytotoxicity to persistent 5'-dRP groups, as opposed to persistent unfilled gaps or multi-nucleotide strand-displacement flaps.

Importance of removing the 5'-dRP group

As discussed above, the necessity of the Pol β lyase domain for MMS sensitivity rescue indicates that the primary protective function against MMS for human Pol β in budding yeast was removal of cytotoxic 5'-dRP groups. A similar requirement for 5'-dRP group removal is also observed for MMS hypersensitivity in mammalian cells [26]. The fact that both of these eukaryotic organisms require this activity underscores the importance for further investigation into the cytotoxic effects of the blocked 5'-end. A need for understanding the various roles of the 5'-dRP group has been highlighted in studies of BER in mammalian cells. Here, poly (ADP-ribose) polymerase (PARP) inhibitor sensitization of cells to MMS-induced killing is dependent on the presence of the 5'-dRP group [27]. The topic is timely as PARP inhibitors are currently being evaluated in cancer chemotherapy [28]. Although the budding yeast system does not contain the PARP enzyme, this system can nonetheless inform us about the metabolism of the 5'-dRP group in BER intermediates.

One likely outcome of failure to remove the 5'-dRP group is a block in DNA ligation, creating persistent strand breaks. Previous reports demonstrated that MMS treatment in strains lacking Rad27 produced single-strand breaks [16,29], but did not address the removal of the 5'-dRP group specifically. Our results suggested a key function of Rad27 in protection against MMS is to unmask a ligatable strand with a 5'-dRP blocked end, but this effect may be to enable a repair system other than BER. Interestingly, the wild-type extract showed minimal *in vitro* BER activity (Figures 3 and 4). Thus, any short gaps formed after Rad27 excision did not appear to be substrates for the endogenous DNA polymerases. Yet, removal of the 5'-dRP group also could be a critical step in multiple other types of DNA repair, where 5'-dRP removal is necessary for efficient ligation. The fact that our genetic background was lacking only in Rad27, and not other known DNA end-tailoring enzymes, suggests these enzymes were unable to process substrates with the 5'-dRP group. It is also noteworthy that yeast Trf4, known to possess 5'-dRP lyase activity [30], appeared unable to reverse the MMS sensitivity. Nevertheless, endogenous Trf4 activity may have provided for the weak *in vitro* BER product formation observed with extract from the *rad27::polB-3K* strain (Figures 3 and 4). In wild-type cells, it seems likely that Rad27 contributes the major 5'-dRP removal function through flap excision.

We chose not to delete *POLA*, the X-family polymerase in *S. cerevisiae* [24,31], as it has not been implicated in gap filling during BER, but instead is involved in non-homologous end-joining [32,33]. The observation of a lack of *in vitro* BER (Figures 3 and 4)

in the wild-type extract was not surprising in light of earlier results [24] and suggests the gap-filling functions of yeast Pol 4 have evolved to specialize in the non-homologous end-joining branch of DNA repair. Since we found that the polymerase function of Pol β was dispensable for MMS rescue, it is likely that yeast utilizes Rad27 to remove the cytotoxic 5'-dRP group and that another repair pathway or process is recruited to complete the repair.

Supporting Information

Figure S1 Evidence of pol β -mediated BER in *S. cerevisiae* strain carrying human pol β . (A) Schematic representations of the substrate and the reaction scheme are shown. (B) *In vitro* BER capacity of *S. cerevisiae* extracts. Repair reactions were incubated either with extracts from *wild-type* (lanes 1–3), *rad27::POL β* (lanes 4–6), or *rad27::POL β* supplemented with human DNA ligase I (lanes 7–9), respectively. Reaction mixtures (15 μ l each) were assembled on ice as described under Material and Methods. The repair was initiated by transferring the reaction mixtures to 35°C. Aliquots (4.5 μ l each) were withdrawn at 10, 20 and 40 min. The repair reaction was terminated by addition of an equal volume of DNA gel-loading buffer. After incubation at 75°C

for 2 min, the reaction products were separated by electrophoresis in a 16% polyacrylamide gel containing 8 M urea. A Typhoon PhosphorImager was used for gel scanning and imaging. The positions of ligated BER product and un-ligated BER intermediate are indicated.

(TIF)

Acknowledgments

We thank Donna Stefanick for providing assistance with gamma irradiation studies. We thank Dmitry Gordenin for discussion and advice during the early stages of this work, and we are deeply indebted to Melissa Adkins and Jessica Williams for assistance and advice throughout. We also thank Bill Beard, Natalie Gassman, Julie Horton and Jessica Williams for critical reading of the manuscript and Bonnie Mesmer for editorial assistance.

Author Contributions

Conceived and designed the experiments: MH VP RP SHW. Performed the experiments: MH VP RP. Analyzed the data: MH VP RP SHW. Contributed reagents/materials/analysis tools: MH VP RP SHW. Wrote the paper: MH RP SHW.

References

- Jacobs AL, Schar P (2012) DNA glycosylases: in DNA repair and beyond. *Chromosoma* 121: 1–20.
- Fu D, Calvo JA, Samson LD (2012) Balancing repair and tolerance of DNA damage caused by alkylating agents. *Nat Rev Cancer*.
- Daley JM, Wilson TE, Ramotar D (2010) Genetic interactions between HNT3/Aprataxin and RAD27/FEN1 suggest parallel pathways for 5' end processing during base excision repair. *DNA Repair* 9: 690–699.
- Khodyreva SN, Prasad R, Iilina ES, Sukhanova MV, Kutuzov MM, et al. (2010) Apurinic/aprimidinic (AP) site recognition by the 5'-dRP/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1). *Proc Natl Acad Sci U S A* 107: 22090–22095.
- Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. *Nat Rev Cancer* 10: 293–301.
- Prasad R, Beard WA, Batra VK, Liu Y, Shock DD, et al. (2011) A review of recent experiments on step-to-step “hand-off” of the DNA intermediates in mammalian base excision repair pathways. *Mol Biol* 45: 586–600.
- Beard WA, Prasad R, Wilson SH (2006) Activities and mechanism of DNA polymerase beta. *Methods Enzymol* 408: 91–107.
- Prasad R, Beard WA, Chyan JY, Maciejewski MW, Mullen GP, et al. (1998) Functional analysis of the amino-terminal 8-kDa domain of DNA polymerase beta as revealed by site-directed mutagenesis. DNA binding and 5'-deoxyribose phosphate lyase activities. *J Biol Chem* 273: 11121–11126.
- Robertson AB, Klungland A, Rognes T, Leiros I (2009) DNA repair in mammalian cells: Base excision repair: the long and short of it. *Cell Mol Life Sci* 66: 981–993.
- Zharkov DO (2008) Base excision DNA repair. *Cell Mol Life Sci* 65: 1544–1565.
- Liu Y, Wilson SH (2012) DNA base excision repair: a mechanism of trinucleotide repeat expansion. *Trends in Biochemical Sciences*: In press.
- Boiteux S, Guillet M (2004) Abasic sites in DNA: repair and biological consequences in *Saccharomyces cerevisiae*. *DNA Repair* 3: 1–12.
- Johnson RE, Kovvali GK, Prakash L, Prakash S (1995) Requirement of the yeast RTH1 5' to 3' exonuclease for the stability of simple repetitive DNA. *Science* 269: 238–240.
- Reagan MS, Pittenger C, Siede W, Friedberg EC (1995) Characterization of a mutant strain of *Saccharomyces cerevisiae* with a deletion of the RAD27 gene, a structural homolog of the RAD2 nucleotide excision repair gene. *J Bacteriol* 177: 364–371.
- Sommers CH, Miller EJ, Dujon B, Prakash S, Prakash L (1995) Conditional lethality of null mutations in RTH1 that encodes the yeast counterpart of a mammalian 5' to 3'-exonuclease required for lagging strand DNA synthesis in reconstituted systems. *J Biol Chem* 270: 4193–4196.
- Ma W, Resnick MA, Gordenin DA (2008) Apn1 and Apn2 endonucleases prevent accumulation of repair-associated DNA breaks in budding yeast as revealed by direct chromosomal analysis. *Nucleic Acids Res* 36: 1836–1846.
- Wu X, Wang Z (1999) Relationships between yeast Rad27 and Apn1 in response to apurinic/aprimidinic (AP) sites in DNA. *Nucleic Acids Res* 27: 956–962.
- Beard WA, Wilson SH (1995) Purification and domain-mapping of mammalian DNA polymerase beta. *Methods Enzymol* 262: 98–107.
- Slupphaug G, Eftedal I, Kavli B, Bharati S, Helle NM, et al. (1995) Properties of a recombinant human uracil-DNA glycosylase from the UNG gene and evidence that UNG encodes the major uracil-DNA glycosylase. *Biochemistry* 34: 128–138.
- Wang YC, Burkhart WA, Mackey ZB, Moyer MB, Ramos W, et al. (1994) Mammalian DNA ligase II is highly homologous with vaccinia DNA ligase. Identification of the DNA ligase II active site for enzyme-adenylate formation. *J Biol Chem* 269: 31923–31928.
- Storici F, Resnick MA (2006) The delitto perfetto approach to in vivo site-directed mutagenesis and chromosome rearrangements with synthetic oligonucleotides in yeast. *Methods Enzymol* 409: 329–345.
- Prasad R, Bebenek K, Hou E, Shock DD, Beard WA, et al. (2003) Localization of the deoxyribose phosphate lyase active site in human DNA polymerase iota by controlled proteolysis. *J Biol Chem* 278: 29649–29654.
- Menge KL, Hostomsky Z, Nodes BR, Hudson GO, Rahmati S, et al. (1995) Structure-function analysis of the mammalian DNA polymerase beta active site: role of aspartic acid 256, arginine 254, and arginine 258 in nucleotidyl transfer. *Biochemistry* 34: 15934–15942.
- Prasad R, Widen SG, Singhal RK, Watkins J, Prakash L, et al. (1993) Yeast open reading frame YCR14C encodes a DNA beta-polymerase-like enzyme. *Nucleic Acids Res* 21: 5301–5307.
- Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. *Nat Rev Cancer* 6: 789–802.
- Sobol RW, Prasad R, Evenski A, Baker A, Yang XP, et al. (2000) The lyase activity of the DNA repair protein beta-polymerase protects from DNA-damage-induced cytotoxicity. *Nature* 405: 807–810.
- Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, et al. (2008) XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. *Cell Res* 18: 48–63.
- Ellisen LW (2011) PARP inhibitors in cancer therapy: promise, progress, and puzzles. *Cancer Cell* 19: 165–167.
- Ma W, Panduri V, Sterling JF, Van Houten B, Gordenin DA, et al. (2009) The transition of closely opposed lesions to double-strand breaks during long-patch base excision repair is prevented by the coordinated action of DNA polymerase delta and Rad27/Fen1. *Mol Cell Biol* 29: 1212–1221.
- Gellon L, Carson DR, Carson JP, Demple B (2008) Intrinsic 5'-deoxyribose-5-phosphate lyase activity in *Saccharomyces cerevisiae* Trf4 protein with a possible role in base excision DNA repair. *DNA Repair* 7: 187–198.
- Shimizu K, Santocanale C, Ropp PA, Longhese MP, Plevani P, et al. (1993) Purification and characterization of a new DNA polymerase from budding yeast *Saccharomyces cerevisiae*. A probable homolog of mammalian DNA polymerase beta. *J Biol Chem* 268: 27148–27153.
- Tseng HM, Tomkinson AE (2004) Processing and joining of DNA ends coordinated by interactions among Dnl4/Lif1, Pol4, and FEN-1. *J Biol Chem* 279: 47580–47588.
- Wilson TE, Lieber MR (1999) Efficient processing of DNA ends during yeast nonhomologous end joining. Evidence for a DNA polymerase beta (Pol4)-dependent pathway. *J Biol Chem* 274: 23599–23609.